Inhibikase Therapeutics (IKT) Share-based Compensation (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Share-based Compensation data on file, last reported at $5.6 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 172.24% year-over-year to $5.6 million in Q1 2026; TTM through Mar 2026 was $18.8 million, a 85.87% increase from a year earlier, with the FY2025 full-year figure at $43.6 million, up 435.13% from the prior year.
• Share-based Compensation for Q1 2026 stood at $5.6 million, up from $4.5 million in the prior quarter.
• Over the last five years, Share-based Compensation for IKT reached as high as $7.9 million in Q4 2024 and fell as low as $30697.0 in Q2 2024.
• Historically, Share-based Compensation has averaged $1.8 million across 5 years, with a median of $129781.0 in 2023.
• Across the five-year window, Share-based Compensation plunged 79.15% in 2022 and surged 13610.6% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $100363.0 in 2022, then increased by 21.81% to $122249.0 in 2023, then jumped by 6369.14% to $7.9 million in 2024, then plunged by 42.67% to $4.5 million in 2025, then increased by 22.63% to $5.6 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $5.6 million in Q1 2026, $4.5 million in Q4 2025, and $4.5 million in Q3 2025.